A mandate begins long before the process — with understanding what the business is truly worth, and to whom.
Sell-side: we work with founders and shareholders who have built something valuable and are weighing the right moment and the right partner. We prepare the company, shape its narrative, and run a disciplined process to a signing that protects price, people and legacy. Buy-side: for acquirers who understand that in luxury and heritage the right acquisition is not the cheapest one, we source proprietary opportunities, conduct sector due diligence, and structure approaches that respect the identity of the target.
We help companies structure and raise growth capital — convertible instruments, bridge financing, institutional rounds. Having operated in both private and listed environments, we bring the investor's perspective to the table: the equity story, the materials and the cadence that let capital understand, and fund, the strategy. The investor-relations discipline is built in, not bolted on.
We work on a strictly confidential basis. Mandates are not publicly disclosed without client consent. Selected references available upon request, under NDA.
We choose depth over breadth, operating where we know the economics, the buyers, and the difference between a brand and a business.
Heritage maisons and family-owned companies. Fashion, home linen, perfume, leather goods, gastronomy, hospitality. We understand the specific economics of heritage brands: the role of founder identity in enterprise value, the challenge of transmitting savoir-faire, the difference between a brand and a business. We publish BLUE. — the only advisory firm in this sector with an editorial product of this quality.
Biopharmaceuticals, medtech, digital health, gene therapy. Listed and private companies, across European and North American markets. Our healthcare practice is rooted in seven years of senior CFO experience at a Paris-listed gene therapy company. We understand regulatory environments, clinical-development economics, and the dynamics of financing early- and growth-stage businesses.
Where the two worlds meet. A corrective lens is a medical object; the frame, a fashion object. Eyewear is the proof that our two worlds were never truly separate.
I have spent nearly three decades at the intersection of finance, aesthetics, and sound — not because I could not choose between them, but because I believe the intersection is more interesting than any of the disciplines alone.
As CFO of GenSight Biologics, a Paris-listed gene therapy company, I led financing operations through complex liquidity situations, managed institutional investor relationships, and advised the board on strategic matters. Before that, I built Blueballoon Capital as a boutique advisory practice focused on two sectors I understand deeply: luxury brands and healthcare. That healthcare conviction was earned over fifteen years leading corporate M&A at Cegedim, the listed healthcare-technology group, where I executed acquisitions including Médimust and Ximantix.
I edit BLUE., a quarterly luxury and fashion magazine that I founded as the public expression of everything I believe about the relationship between capital and culture. I compose original music for its pages under the Sunblue Studio name. These are not side projects. They are the same work, in different languages.
I am based in Paris, at 10 Place Vendôme. I work in French and English, and across healthcare and luxury without preferring one to the other. If you are considering a transaction and want a conversation with someone who understands both the numbers and the story behind them — I would be glad to speak.
Further references available in confidence, by introduction.
A personal reflection on the business of luxury. One market moment, one point of view, three hundred words — published on LinkedIn, archived here.
We do not have a contact form. We have an email address — and we read every message ourselves. If a time suits you better than a message, reserve one directly.